Adoptive immunotherapy for EBV-associated malignancies
- PMID: 15621775
- DOI: 10.1080/10428190400002202
Adoptive immunotherapy for EBV-associated malignancies
Abstract
Latent Epstein-Barr virus (EBV) infection is associated with a diverse group of malignancies including Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma (NPC), and lymphoproliferative disease (LPD). EBV proteins expressed in these malignancies provide targets for the adoptive immunotherapy with antigen-specific cytotoxic T cells (CTL) and EBV-specific CTL have been used successfully for the prophylaxis and treatment of EBV-LPD post hematopoietic stem cell transplantation (HSCT). The clinical experience with EBV-specific CTL for other EBV-associated malignancies such as Hodgkin's disease and NPC is limited and the results obtained so far indicate that EBV-specific CTL are less effective than for EBV-LPD post HSCT. Decreased CTL efficacy most likely reflect immune evasion strategies by tumor cells such as down regulation of immunodominant EBV proteins and secretion of inhibitory cytokines. To overcome these immune evasion strategies a number of approaches have been developed including targeting CTL to subdominant EBV antigens and genetically modifying CTL to increase their potency.
Similar articles
-
Treatment of Epstein-Barr virus-associated malignancies with specific T cells.Adv Cancer Res. 2002;84:175-201. doi: 10.1016/s0065-230x(02)84006-4. Adv Cancer Res. 2002. PMID: 11883527 Review.
-
Immunotherapy for Epstein-Barr virus-associated cancers in children.Oncologist. 2003;8(1):83-98. doi: 10.1634/theoncologist.8-1-83. Oncologist. 2003. PMID: 12604735 Review.
-
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.Recent Results Cancer Res. 2002;159:123-33. doi: 10.1007/978-3-642-56352-2_15. Recent Results Cancer Res. 2002. PMID: 11785836
-
Immunotherapy for Epstein-Barr virus-associated tumors.Leuk Lymphoma. 2004 Oct;45(10):1981-7. doi: 10.1080/10428190410001700831. Leuk Lymphoma. 2004. PMID: 15370241 Review.
-
Adoptive T-Cell Immunotherapy.Curr Top Microbiol Immunol. 2015;391:427-54. doi: 10.1007/978-3-319-22834-1_15. Curr Top Microbiol Immunol. 2015. PMID: 26428384 Free PMC article. Review.
Cited by
-
Challenges and future perspectives of T cell immunotherapy in cancer.Immunol Lett. 2015 Aug;166(2):117-33. doi: 10.1016/j.imlet.2015.05.018. Epub 2015 Jun 19. Immunol Lett. 2015. PMID: 26096822 Free PMC article. Review.
-
Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients.Cancer Res. 2008 Jul 15;68(14):5869-77. doi: 10.1158/0008-5472.CAN-07-6838. Cancer Res. 2008. PMID: 18632641 Free PMC article.
-
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.Cytotherapy. 2007;9(7):613-29. doi: 10.1080/14653240701650320. Cytotherapy. 2007. PMID: 17943498 Free PMC article. Review.
-
The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.Haematologica. 2010 Oct;95(10):1769-77. doi: 10.3324/haematol.2010.023689. Epub 2010 Apr 26. Haematologica. 2010. PMID: 20421267 Free PMC article. Review.
-
TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.Cancer Immunol Immunother. 2009 May;58(5):809-22. doi: 10.1007/s00262-008-0649-4. Epub 2009 Feb 3. Cancer Immunol Immunother. 2009. PMID: 19189103 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
